معرفی
Roles and Affiliations: Distinguished Professor Magdalena Plebanski is a leader in immunology and bioengineering research at RMIT University, serving as Director of the Biomedical & Health Innovation Enabling Impact Platform (BHI EIP) and Head of the Translational Immunology and Nanotechnology Theme. She leads the Cancer, Ageing, and Vaccines Laboratory within the School of Health and Biomedical Sciences. Her roles include mentoring researchers across disciplines and driving initiatives like the 'Pathways to Healthy Ageing' project.
Education and Career Highlights: Plebanski holds honorary fellowships from the University of Oxford and has held adjunct professorships at Monash University and the University of Tasmania. She has over 40 patents in 10 patent families, leading to successful biotechnology ventures such as Panvax Pty Ltd and PX Biosolutions Pty Ltd.
Research Interests: Her work focuses on ovarian cancer diagnostics and therapies (e.g., gold-based immunotherapies, biomarkers in clinical trials like SOLACE2), aging’s impact on immunity, and vaccine design using nanoparticles. She employs epigenetics, bioinformatics, and big data to study immune responses in aging populations and vulnerable groups like the elderly and pregnant women.
Key Achievements: Over $30M in research funding, 200+ peer-reviewed publications in top journals (Nature, Science, Immunity), and impactful initiatives like the Mental Health Innovation Network. Awards include the RMIT Vice-Chancellor’s Research Excellence Award (2020) and NHMRC Senior Research Fellowships.
Clinical and Collaborative Work: Collaborates with RMIT chemists and nanoengineers on point-of-care diagnostics and immunotherapies. Leads international projects, such as the Australia-Europe Digital Health webinar and the SOLACE2 ovarian cancer trial. Her work bridges academia, industry, and global health challenges.
